Synapse Open Synapse
Biology

Teva’s pipeline in 2027: Can it sustain its transformation?

Labiotech.eu · · 5 min read

While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative pipeline.

Latest from Labiotech.eu